Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Not Confirmed
Not Confirmed
05-06 June, 2025
Not Confirmed
Not Confirmed
05-06 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Industry Trade Show
Not Confirmed
05-06 June, 2025
Industry Trade Show
Not Confirmed
05-06 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
01 Jun 2023
// BUSINESSWIRE
01 Jun 2023
// Nick Paul Taylor FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/bayer-inks-cedilla-cancer-deal-betting-take-tough-target-will-beat-pfizer-and-chasing-pack#:~:text=Bayer%20inks%20Cedilla%20cancer%20deal%2C%20betting%20take%20on%20tough%20target,Pfizer%20and%20the%20chasing%20pack&text=Bayer%20is%20joining%20Blueprint%20Medicines,to%20the%20more%20advanced%20rivals.
23 Feb 2023
// Kyle LaHucik ENDPTS
https://endpts.com/third-rock-shrinks-another-biotech-as-cedilla-restructures-ceo-and-cbo-depart/
26 Oct 2021
// K. LaHucik FIERCEBIOTECH
https://www.fiercebiotech.com/biotech/cedilla-tops-off-series-b-additional-25m-to-test-drugs-mesothelioma-certain-breast-cancers
21 Oct 2021
// BIOSPACE
https://www.biospace.com/article/releases/cedilla-therapeutics-unveils-lead-programs-for-the-conditional-inhibition-of-tead-and-cdk2-two-high-value-and-historically-undruggable-cancer-drivers/?s=71
30 Nov 2020
// BUSINESSWIRE
ABOUT THIS PAGE